The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Open accessAbstract
BACKGROUND: Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe. HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly. RESULTS: Of 12,320 women who were screened, 5029 were enrolled in the study. The rate of retention in the study was 91% during 5509 person-years of follow-up. A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years. In the modified intention-to-treat analysis, the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21). In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively. Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous. Detection of TFV in plasma was negatively associated with characteristics predictive of HIV-1 acquisition. Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P=0.004). We observed no significant differences in the frequencies of other adverse events. CONCLUSIONS: None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis. Adherence to study drugs was low. (Funded by the National Institutes of Health; VOICE ClinicalTrials.gov number, NCT00705679.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Adherence can be low (48), and prevention of HIV infection, especially among women, has not been demonstrated (47,49).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
A Case-Cohort Design for Epidemiologic Cohort Studies and Disease Prevention Trials
Prentice, R. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.1 · Cited by 1,444
Tanser, F. C., Bärnighausen, T., Grapsa, E., Zaidi, J., & Newell, M. (2013) · Science · doi:10.1126/science.1228160 · Cited by 797
Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation
Liu, T. F., & Shafer, R. W. (2006) · Clinical Infectious Diseases · doi:10.1086/503914 · Cited by 661
Complex Surveys: A Guide to Analysis Using R
Lumley, T. (2010) · doi:10.1002/9780470580066 · Cited by 647
Complex Surveys: A Guide to Analysis Using R
Lumley, T. (2010) · Cited by 571
Optimal recall period and response task for self-reported HIV medication adherence
Lu, M., Safren, S. A., Skolnik, P. R., Rogers, W. H., Coady, W., Hardy, H., & Wilson, I. B. (2008) · AIDS and Behavior · doi:10.1007/s10461-007-9261-4 · Cited by 361
van der Straten, A., Stadler, J., Montgomery, E., Hartmann, M., Magazi, B., Mathebula, F., Schwartz, K. D., Laborde, N. D., & Soto-Torres, L. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089118 · Cited by 259
Ware, N. C., Wyatt, M. A., Haberer, J. E., Baeten, J. M., Kintu, A., Psaros, C., Safren, S. A., Tumwesigye, E., Celum, C., & Bangsberg, D. R. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31824a060b · Cited by 259
Karim, S. S. A., Kashuba, A. D. M., Werner, L., & Karim, Q. A. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60878-7 · Cited by 222
Parikh, U. M., Dobard, C., Sharma, S., Cong, M.-E., Jia, H., Martin, A., Pau, C., Hanson, D. L., Guenthner, P. C., Smith, J., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01073-09 · Cited by 186
Cranage, M. P., Sharpe, S. A., Herrera, C., Cope, A. V., Dennis, M. J., Berry, N. J., Ham, C., Heeney, J. L., Rezk, N. L., Kashuba, A. D. M., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050157 · Cited by 151
Acceptability in microbicide and PrEP trials
Mensch, B., van der Straten, A., & Katzen, L. L. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e3283590632 · Cited by 84
Appropriateness of Hydroxyethylcellulose Gel as a Placebo Control in Vaginal Microbicide Trials
Richardson, B. A., Kelly, C., Gita Ramjee, H., Fleming, T. R., Makanani, B., Roberts, S. T., Musara, P., Mkandawire, N., Moench, T. R., Coletti, A., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31828607c5 · Cited by 21
Flagged first, then by citations
Cited by
Sorted by citations
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., Sullivan, A. K., Clarke, A., Reeves, I., Schembri, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00056-2 · Cited by 1,878
Self-citationOn-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Molina, J., Capitant, C., Spire, B., Pialoux, G., Cotte, L., Charreau, I., Tremblay, C. L., Gall, J.-M. L., Cua, É., Pasquet, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506273 · Cited by 1,698
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
Fonner, V. A., Dalglish, S. L., Kennedy, C. E., Baggaley, R. C., O’Reilly, K., Koechlin, F. M., Rodolph, M., Hodges-Mameletzis, I., & Grant, R. M. (2016) · AIDS · doi:10.1097/qad.0000000000001145 · Cited by 1,026
HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities
Kharsany, A. B. M., & Karim, Q. A. (2016) · The Open AIDS Journal · doi:10.2174/1874613601610010034 · Cited by 1,041
Metadata
- Authors
- Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., Hendrix, C. W., Dai, J. Y., Ganesh, S., Mkhize, B., Taljaard, M., Parikh, U. M., Piper, J., Mâsse, B., Grossman, C., Rooney, J., Schwartz, J. L., Watts, H., Marzinke, M. A., Hillier, S. L., McGowan, I. M., & Chirenje, Z. M.
- Affiliations
- University of California, San Francisco (US)
- Harborview Medical Center (US)
- Family Health International 360 (US)
- University of Zimbabwe (ZW)
- Centre for the AIDS Programme of Research in South Africa (ZA)
- University of Pittsburgh (US)
- Johns Hopkins University (US)
- South African Medical Research Council (ZA)
- National Institutes of Health (US)
- Eastern Virginia Medical School (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-05
- Volume
- 372
- Issue
- 6
- Pages
- 509-518
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4341965
- OpenAlex
- W2044369525
- Cited by
- 1,296
- References
- 19
- Citations by year
- 2026: 32 · 2025: 54 · 2024: 59 · 2023: 78 · 2022: 93 · 2021: 143 · 2020: 125 · 2019: 139 · 2018: 122 · 2017: 140 · 2016: 175 · 2015: 131
- FWCI
- 147.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ResearchSpace (University of KwaZulu-Natal) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U01AI068633, UM1AI068615, UM1AI069422, UM1AI106707, UM1AI069436, P30AI094189, UM1AI069530, UM1AI069463, UM1AI069469)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- tenofovir disoproxil fumarate, tenofovir/emtricitabine, HIV pre-exposure prophylaxis, HIV-1 prevention, women, women of reproductive age, antiretroviral resistance, tenofovir resistance, drug safety, adverse events, creatinine elevation
- MeSH terms
- Emtricitabine, Tenofovir, Adenine, Administration, Intravaginal, Administration, Oral, Adolescent, Adult, Deoxycytidine, Drug Therapy, Combination, Female, HIV Seropositivity, Humans, Middle Aged, Surveys and Questionnaires, HIV-1, HIV Infections, Africa South of the Sahara, Drug Resistance, Viral, Anti-Retroviral Agents, Medication Adherence, Young Adult, Organophosphonates, Pre-Exposure Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
